KR101040281B1 - Tat-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 - Google Patents
Tat-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 Download PDFInfo
- Publication number
- KR101040281B1 KR101040281B1 KR1020080082599A KR20080082599A KR101040281B1 KR 101040281 B1 KR101040281 B1 KR 101040281B1 KR 1020080082599 A KR1020080082599 A KR 1020080082599A KR 20080082599 A KR20080082599 A KR 20080082599A KR 101040281 B1 KR101040281 B1 KR 101040281B1
- Authority
- KR
- South Korea
- Prior art keywords
- tat
- cells
- antigen
- cea
- vaccine composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (9)
- 항원 특이 면역반응을 유발할 수 있는 백신 조성물로서,(a) 서열번호 1의 HIV TAT(transactivator protein)의 단백질전달도메인(protein transduction domain, PTD)과 이의 아미노 말단에 연결된 항원을 포함하는 융합단백질,(b) 상기 융합 단백질을 코딩하는 핵산 분자, 또는 (c) 상기 융합 단백질을 코딩하는 폴리뉴클레오티드 서열을 포함하는 재조합 벡터; 및아쥬번트로서 CpG ODN, Poly I:C 또는 이들의 혼합물을 포함하는 백신 조성물.
- 제1항에 있어서, 항원은 암태아항원(CEA)인 것을 특징으로 하는 백신 조성물.
- 제1항에 있어서, 항원은 서열번호 2에 제시된 암태아항원(CEA) D1도메인임을 특징으로 하는 백신 조성물.
- 제1항에 있어서, 항원은 서열번호 3에 제시된 서비빈(SURVIVIN)인 것을 특징으로 하는 백신 조성물.
- 제1항에 있어서, 상기 재조합 벡터는 도 1의 개열지도를 가지는 것을 특징으로 하는 백신 조성물.
- 제1항에 있어서, 상기 재조합 벡터는 도 6의 개열지도를 가지는 것을 특징으로 하는 백신 조성물.
- 삭제
- 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 백신 조성물은 세포독성 T 세포 활성을 증가시키고, 인터페론-γ(IFN-γ) 생성을 증가시키는 것을 특징으로 하는 백신 조성물.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 백신 조성물은 Th1 유형의 면역반응을 유도하는 것을 특징으로 하는 백신 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080082599A KR101040281B1 (ko) | 2008-08-22 | 2008-08-22 | Tat-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080082599A KR101040281B1 (ko) | 2008-08-22 | 2008-08-22 | Tat-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100023696A KR20100023696A (ko) | 2010-03-04 |
KR101040281B1 true KR101040281B1 (ko) | 2011-06-10 |
Family
ID=42175896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080082599A KR101040281B1 (ko) | 2008-08-22 | 2008-08-22 | Tat-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101040281B1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018055060A1 (en) * | 2016-09-21 | 2018-03-29 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
-
2008
- 2008-08-22 KR KR1020080082599A patent/KR101040281B1/ko active IP Right Grant
Non-Patent Citations (3)
Title |
---|
논문2;Cancer Letters* |
논문3;가톨릭대학교* |
논문4;BIOLOGY OF REPRODUCTION* |
Also Published As
Publication number | Publication date |
---|---|
KR20100023696A (ko) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150037326A1 (en) | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen | |
KR20190035795A (ko) | 면역 반응을 조정하기 위한 생체재료 | |
JP6430949B2 (ja) | Gm−csfとil−4のコンジュゲート、組成物、ならびにそれに関連する方法 | |
CN114761438A (zh) | 用于编程细胞外囊泡的重组多肽 | |
KR20020068040A (ko) | 키메라 면역원성 조성물 및 그들을 암호화하는 핵산 | |
JP2020521445A (ja) | Pd−1およびctla−4二重インヒビターペプチド | |
US20220233666A1 (en) | Cancer vaccine | |
US20230074462A1 (en) | Methods and compositions for stimulating immune response | |
WO2019101062A1 (zh) | 重组疫苗及其应用 | |
Woo et al. | Co‐administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG‐oligodeoxynucleotide induces potent antitumor immunity | |
CN110054698A (zh) | 抗cd19抗体的新型cd19-car载体的构建及应用 | |
EP1930427B1 (en) | Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule | |
KR101040281B1 (ko) | Tat-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 | |
JP2022501046A (ja) | アルギナーゼ1ポリペプチド | |
Liu et al. | Enhancement of DNA vaccine potency by sandwiching antigen-coding gene between secondary lymphoid tissue chemokine (SLC) and IgG Fc fragment genes | |
US11154599B2 (en) | Her2/neu immunogenic composition | |
KR20240019135A (ko) | 작제물과 면역자극 화합물의 공동발현 | |
JP2007505601A (ja) | ワクチン | |
CN112011833A (zh) | 筛选和分离肿瘤新生抗原的方法 | |
CA3057318A1 (en) | Recombinant chlamydia-activated b cell platforms and methods of use thereof | |
CA2460809A1 (en) | Polynucleotide vaccine | |
CN116406284A (zh) | 用于癌症治疗的多肽 | |
Moynihan | Engineering immunity: Enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer | |
US20070232558A1 (en) | Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen | |
CN117580852A (zh) | 靶向树突状细胞的新型肽及包含该新型肽的癌症治疗用组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140310 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150603 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160217 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170519 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190603 Year of fee payment: 9 |